Skip to main content

Emcure Pharmaceuticals Share Price in Focus; Receives VAI Classification for Sanand Facility

Written by: Team Angel OneUpdated on: 8 Aug 2026, 9:08 pm IST
Emcure Pharmaceuticals gets VAI status for its Sanand formulations facility after a USFDA inspection conducted in May 2026.
Emcure Pharmaceuticals Share Price in Focus
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Emcure Pharmaceuticals has received a Voluntary Action Indicated (VAI) classification for its formulations facility in Sanand, Ahmedabad, as per an exchange filing dated August 8, 2026.  

The classification follows a US Food and Drug Administration (USFDA) inspection conducted at the site in May 2026. The company has now received the Establishment Inspection Report (EIR). 

Inspection Held in May 

The USFDA inspected the facility from May 6 to May 15, 2026. The site is located at G.I.D.C., Taluka Sanand, Ahmedabad, Gujarat. Emcure had informed the stock exchanges about the inspection on May 16, 2026. 

Facility Gets VAI Classification 

The EIR issued by the USFDA has classified the inspection status of the Sanand facility as VAI. Emcure noted that the inspection stands closed following the classification. The latest filing does not provide the observations recorded by the regulator during the inspection. 

No Inspection Details Provided 

Emcure has not disclosed the specific observations from the USFDA inspection in its latest filing. The company has also not mentioned any corrective actions, timelines or other requirements arising from the inspection. The filing only gives the classification and confirms that the inspection has been closed. 

Sanand Formulations Facility 

The facility inspected by the USFDA is located in G.I.D.C., Taluka Sanand, Ahmedabad-382110. The inspection covered the site over 10 days in May. Emcure’s filing does not give further information on the inspection findings or any action to be taken after the review. 

Read MoreJindal Worldwide Share Price in Focus; Board Approves Rights Issue of Upto ₹650 Crore! 

Emcure Pharmaceuticals Share Price Performance  

As of August 7, 2026, 3:30 pm, Emcure Pharmaceuticals share price closed at ₹1,982.00, a 2.34% increase from the previous closing price. 

Conclusion 

Emcure’s Sanand formulations facility received VAI classification following the USFDA inspection conducted in May 2026. The inspection now stands closed. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Published on: Aug 8, 2026, 3:38 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS

Enjoy ₹0 Account Opening Charges

Get the link to download the App

Scan this QR code to download the app
Get it on Google PlayDownload on the App Store

Open Free Demat Account!

Join our 3.5 Cr+ happy customers
+91